3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
2
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
Everolimus
10
Octreotide
7
pasireotide
5
lanreotide
5
gallium Ga 68 dotatate
4
lutetium Lu 177 dotatate
3
cabozantinib
3
Sunitinib
3
Nivolumab
3
ganitumab
2
Temozolomide
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
zimberelimab
1
veliparib
1
telotristat ethyl
1
surufatinib
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
olaparib
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoid Tumor
×
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled